Dermovate

Страна: Армения

Язык: английский

Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Активный ингредиент:

clobetasol (clobetasol propionate)

Доступна с:

GlaxoSmithKline Pharmaceuticals S.A.

ИНН (Международная Имя):

clobetasol (clobetasol propionate)

дозировка:

0,5mg/g

Фармацевтическая форма:

cream

Тип рецепта:

Prescription

тонкая брошюра

DERMOVATE
Clobetasol propionate
QUALITATIVE AND QUANTITATIVE COMPOSITION
_DERMOVATE_ Cream and Ointment contains Clobetasol propionate
0.05 % w/w.
PHARMACEUTICAL FORM
Cream and Ointment.
CLINICAL PARTICULARS
Indications
_DERMOVATE_ is a very potent topical corticosteroid indicated for
adults, elderly and children over 1 year for the relief of the
inflammatory and pruritic manifestations of steroid responsive
dermatoses.
These include the following:
-
Psoriasis (excluding widespread plaque psoriasis).
-
Recalcitrant dermatoses
-
Lichen planus
-
Discoid lupus erythematosus
-
Other skin conditions which do not respond satisfactorily to less
potent steroids
Dosage and Administration
_Ointment _
Ointments are especially appropriate for dry, lichenified or scaly
lesions.
_Cream_
Creams are especially appropriate for moist or weeping surfaces.
Adults, Elderly and Children over 1 year
Apply thinly and gently rub in using only enough to cover the entire
affected area once or twice a day for up to 4 weeks until
improvement occurs, then reduce the frequency of application or
change the treatment to a less potent preparation. Allow adequate
time for absorption after each application before applying an
emollient.
Repeated short courses of _DERMOVATE_ may be used to control
exacerbations.
In more resistant lesions, especially where there is hyperkeratosis,
the effect of _DERMOVATE_ can be enhanced, if necessary, by
occluding the treatment area with polythene film.
Overnight occlusion only is usually adequate to bring about a
satisfactory response. Thereafter improvement can usually be
maintained by application without occlusion.
If the condition worsens or does not improve within 2-4 weeks,
treatment and diagnosis should be re-evaluated.
Treatment should not be continued for more than 4 weeks. If
continuous treatment is necessary, a less potent preparation should
be used.
The maximum weekly dose should not exceed 50gms/week.
Atopic dermatitis (eczema)
Therapy with _DERMOVATE_ cream and ointment should be gradually
discontinued

Характеристики продукта

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
DERMOVATE™, CLOBETASOL PROPIONATE
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_DERMOVATE_ Cream and Ointment contains Clobetasol propionate 0.05 %
w/w.
3.
PHARMACEUTICAL FORM
Cream and Ointment.
4.
CLINICAL PARTICULARS
4.1 INDICATIONS
_DERMOVATE_ is a very potent topical corticosteroid indicated for
adults, elderly and children over
1 year for the relief of the inflammatory and pruritic manifestations
of steroid responsive
dermatoses.
These include the following:
-
Psoriasis (excluding widespread plaque psoriasis).
-
Recalcitrant dermatoses
-
Lichen planus
-
Discoid lupus erythematosus
-
Other skin conditions which do not respond satisfactorily to less
potent steroids
4.2 DOSAGE AND ADMINISTRATION_ _
_OINTMENT_
Ointments are especially appropriate for dry, lichenified or scaly
lesions.
_CREAM _
Creams are especially appropriate for moist or weeping surfaces.
ADULTS, ELDERLY AND CHILDREN OVER 1 YEAR
Apply thinly and gently rub in using only enough to cover the entire
affected area once or twice a
day for up to 4 weeks until improvement occurs,
then reduce the frequency of application or
change the treatment to a less potent preparation. Allow adequate time
for absorption after each
application before applying an emollient.
Repeated short courses of _DERMOVATE_ may be used to control
exacerbations.
In more resistant lesions, especially where there is hyperkeratosis,
the effect of _DERMOVATE_ can
be enhanced, if necessary, by occluding the treatment area with
polythene film.
Overnight occlusion only is usually adequate to bring about a
satisfactory response. Thereafter
improvement can usually be maintained by application without
occlusion.
If the condition worsens or does not improve within 2-4 weeks,
treatment and diagnosis should be
re-evaluated.
Treatment should not be continued for more than 4 weeks. If continuous
treatment is necessary, a
less potent preparation should be used.
The maximum weekly dose should not exceed 50gms/week.
ATOPIC DERM